A cross-border outbreak of Salmonella Mbandaka ST413 has been ongoing in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) for over two years since September 2021, as detailed in an updated joint Rapid Outbreak Assessment by the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA).
In this episode we take a closer look at the data collection for respiratory viruses and why we should take this more seriously than just a cough or a sneeze.
Resistance of Salmonella and Campylobacter bacteria to commonly used antimicrobials continues to be observed frequently in humans and animals, according to a report issued today by EFSA and ECDC.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
Campylobacteriosis and salmonellosis were the most frequently reported zoonotic diseases in humans in the EU in 2022. For West Nile virus, an increase of the number of infections was observed.
ECDC and World Health Organization (WHO) Regional Office for Europe have jointly developed the European Respiratory Virus Surveillance Summary (ERVISS), an interactive surveillance data dashboard for influenza, respiratory syncytial virus (RSV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that also features a weekly epidemiological summary.
As autumn moves to winter, the WHO/Europe, EC and ECDC are issuing a clear, urgent message: people who remain unprotected against both COVID-19 and seasonal influenza – especially the most vulnerable and at-risk – should take up any offer for vaccination to prevent or mitigate the impact of these co-circulating respiratory infections.